JPMorgan raised Regeneron Pharmaceuticals (NASDAQ:REGN) price target from $900 to $950
JPMorgan analyst Chris Schott maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $900 to $950.
JPMorgan raised Regeneron Pharmaceuticals (NASDAQ:REGN) price target from $900 to $950 Read Post »